Thomas A Prohaska

1.6k total citations · 2 hit papers
13 papers, 610 citations indexed

About

Thomas A Prohaska is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Immunology. According to data from OpenAlex, Thomas A Prohaska has authored 13 papers receiving a total of 610 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Cardiology and Cardiovascular Medicine, 6 papers in Endocrinology, Diabetes and Metabolism and 5 papers in Immunology. Recurrent topics in Thomas A Prohaska's work include Lipid metabolism and disorders (6 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (4 papers) and Immune Cell Function and Interaction (4 papers). Thomas A Prohaska is often cited by papers focused on Lipid metabolism and disorders (6 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (4 papers) and Immune Cell Function and Interaction (4 papers). Thomas A Prohaska collaborates with scholars based in United States, Austria and Brazil. Thomas A Prohaska's co-authors include Sotirios Tsimikas, Joseph L. Witztum, Ewa Karwatowska‐Prokopczuk, Coleen A. McNamara, Prasad Srikakulapu, Shuting Xia, Angela M. Taylor, Chantel McSkimming, Heather M. Perry and Veronica J. Alexander and has published in prestigious journals such as New England Journal of Medicine, The Journal of Immunology and PLoS ONE.

In The Last Decade

Thomas A Prohaska

13 papers receiving 607 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome

2024 112 citations Ewa Karwatowska‐Prokopczuk, Robert A. Hegele et al. New England Journal of Medicine profile →
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk

2024 102 citations Brian A. Bergmark, Nicholas Marston et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas A Prohaska United States	10	250	215	149	145	133	13	610
Ashley J. Wilhelm United States	11	313 1.3×	62 0.3×	157 1.1×	148 1.0×	62 0.5×	13	511
Mustafa Yalçınkaya United States	13	196 0.8×	47 0.2×	140 0.9×	243 1.7×	58 0.4×	22	579
Iris Cardolini Italy	8	186 0.7×	73 0.3×	58 0.4×	102 0.7×	36 0.3×	8	441
Flora Saint-Charles France	11	354 1.4×	34 0.2×	164 1.1×	147 1.0×	82 0.6×	14	604
Arnaud D. Hauer Netherlands	11	451 1.8×	77 0.4×	84 0.6×	172 1.2×	25 0.2×	17	651
T Okura Japan	9	73 0.3×	158 0.7×	62 0.4×	262 1.8×	83 0.6×	22	515
Yuanhong Ma Canada	15	106 0.4×	359 1.7×	315 2.1×	176 1.2×	327 2.5×	25	775
Alphonse Hubsch Switzerland	9	117 0.5×	47 0.2×	120 0.8×	106 0.7×	85 0.6×	22	427
Kunimaro Furuta Japan	17	90 0.4×	44 0.2×	109 0.7×	293 2.0×	71 0.5×	32	776
Taishi Sasaoka Japan	11	149 0.6×	138 0.6×	91 0.6×	177 1.2×	26 0.2×	17	471

Countries citing papers authored by Thomas A Prohaska

Since Specialization

Citations

This map shows the geographic impact of Thomas A Prohaska's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas A Prohaska with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas A Prohaska more than expected).

Fields of papers citing papers by Thomas A Prohaska

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas A Prohaska. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas A Prohaska. The network helps show where Thomas A Prohaska may publish in the future.

Co-authorship network of co-authors of Thomas A Prohaska

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas A Prohaska. A scholar is included among the top collaborators of Thomas A Prohaska based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas A Prohaska. Thomas A Prohaska is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Marston, Nicholas, Brian A. Bergmark, Veronica J. Alexander, et al.. (2025). Design and rationale of the CORE-TIMI 72a and CORE2-TIMI 72b trials of olezarsen in patients with severe hypertriglyceridemia. American Heart Journal. 286. 125–135. 4 indexed citations

Bergmark, Brian A., Nicholas Marston, Thomas A Prohaska, et al.. (2025). Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk: Rationale and design of the Essence–TIMI 73b trial. American Heart Journal. 286. 116–124. 3 indexed citations

Bergmark, Brian A., Nicholas Marston, Thomas A Prohaska, et al.. (2025). Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. New England Journal of Medicine. 393(13). 1279–1291. 9 indexed citations

Karwatowska‐Prokopczuk, Ewa, Robert A. Hegele, Marcello Arca, et al.. (2024). Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome. New England Journal of Medicine. 390(19). 1781–1792. 112 indexed citations breakdown →

Bergmark, Brian A., Nicholas Marston, Thomas A Prohaska, et al.. (2024). Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk. New England Journal of Medicine. 390(19). 1770–1780. 102 indexed citations breakdown →

Prohaska, Thomas A, Veronica J. Alexander, Ewa Karwatowska‐Prokopczuk, et al.. (2023). APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia. Journal of clinical lipidology. 17(3). 406–411. 36 indexed citations

Shen, Zeyang, Rick Z. Li, Thomas A Prohaska, et al.. (2022). Systematic analysis of naturally occurring insertions and deletions that alter transcription factor spacing identifies tolerant and sensitive transcription factor pairs. eLife. 11. 9 indexed citations

Srikakulapu, Prasad, Tanyaporn Pattarabanjird, Aditi Upadhye, et al.. (2022). B-1b Cells Have Unique Functional Traits Compared to B-1a Cells at Homeostasis and in Aged Hyperlipidemic Mice With Atherosclerosis. Frontiers in Immunology. 13. 909475–909475. 9 indexed citations

Prohaska, Thomas A, Xuchu Que, Cody J. Diehl, et al.. (2018). Massively Parallel Sequencing of Peritoneal and Splenic B Cell Repertoires Highlights Unique Properties of B-1 Cell Antibodies. The Journal of Immunology. 200(5). 1702–1717. 37 indexed citations

10.

Harmon, Daniel B., Prasad Srikakulapu, Jennifer L. Kaplan, et al.. (2016). Protective Role for B-1b B Cells and IgM in Obesity-Associated Inflammation, Glucose Intolerance, and Insulin Resistance. Arteriosclerosis Thrombosis and Vascular Biology. 36(4). 682–691. 78 indexed citations

11.

Perry, Heather M., Ayelet Gonen, Thomas A Prohaska, et al.. (2015). B-1b Cells Secrete Atheroprotective IgM and Attenuate Atherosclerosis. Circulation Research. 117(3). e28–39. 110 indexed citations

12.

Tsiantoulas, Dimitrios, Thomas Perkmann, Taras Afonyushkin, et al.. (2014). Circulating microparticles carry oxidation-specific epitopes and are recognized by natural IgM antibodies. Journal of Lipid Research. 56(2). 440–448. 91 indexed citations

13.

Prohaska, Thomas A, et al.. (2012). Interaction of Protein C Inhibitor with the Type II Transmembrane Serine Protease Enteropeptidase. PLoS ONE. 7(6). e39262–e39262. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact